- Keryx Biopharmaceuticals (KERX -11%) slumps again on a 5x surge in volume. Shares are off ~17% from the August 28 peak of $18.48. On Friday, the FDA approved ferric citrate for the control of serum phosphate levels in patients with chronic kidney disease on dialysis.
Keryx down again today
Recommended For You
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| KERX | - | - |
| Keryx Biopharmaceuticals, Inc. | ||